Alpha7 nAChR PAMs for HIV-Associated Neurological Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for HIV-associated neurological disorders (HAND) are inadequate, as antiretroviral therapies lack significant penetration into the CNS and fail to effectively address behavioral impairments, neuroinflammation, and neuronal injury, with HIV viral protein Tat being a major pathogenic factor.
Innovation Solution
Administration of a positive allosteric modulator (PAM) of the α7 nicotinic acetylcholine receptor, such as PNU-120596, to modulate the p38 MAPK signaling pathway, thereby alleviating behavioral impairments and neuropathologies associated with HAND.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If combined antiretroviral therapy (cART) is used to suppress HIV replication, then HIV replication is suppressed and immune function is improved, but HAND becomes more prevalent and neurological symptoms worsen
Solution Approach 1:
The patent introduces α7 nAChR PAMs as an intermediary therapeutic agent that addresses the neurological side effects of cART. This mediator targets the downstream pathological effects (Tat-induced neuroinflammation and neuronal injury) without interfering with the primary antiviral mechanism of cART, thus resolving the contradiction between viral suppression and neurological health
Solution Approach 2:
The treatment approach is segmented into two distinct components: cART for viral suppression and α7 nAChR PAMs for neurological protection. This segmentation allows each therapy to target specific aspects of the disease without interfering with the other, addressing both the viral infection and its neurological consequences independently
2Reliability
If current cART regimens are used, then HIV replication is suppressed, but drug penetration into CNS is insufficient and HAND treatment is ineffective
Solution Approach 1:
The patent employs α7 nAChR PAMs as a mediator that can effectively cross the blood-brain barrier and act within the CNS. This intermediary substance addresses the neurological pathology directly in the target tissue, overcoming the limitation of poor cART penetration into the central nervous system
Solution Approach 2:
The patent changes the therapeutic parameter from antiviral agents to neuroprotective agents that have different pharmacokinetic properties. The α7 nAChR PAMs possess enhanced CNS penetration capabilities compared to antiretroviral drugs, allowing effective delivery of the therapeutic substance to the neurological target sites
3Quantity of substance
If Tat expression is not inhibited, then HIV viral protein production continues, but neuroinflammation and neuronal injury worsen
Solution Approach 1:
The patent converts the harmful effect of Tat expression into a therapeutic opportunity by targeting the specific pathological pathways downstream of Tat. Rather than attempting to eliminate Tat production entirely, the approach uses α7 nAChR activation to counteract the harmful effects of Tat-induced neuroinflammation and neuronal injury, effectively converting the presence of the pathogenic protein into a manageable condition
Solution Approach 2:
The patent introduces α7 nAChR PAMs as an intermediary that intervenes in the pathological cascade initiated by Tat. This mediator blocks the transmission of harmful signals from Tat to neuronal targets, preventing the development of neuroinflammation and neuronal injury even in the presence of continued Tat production
Data Source
AI summary
In the present disclosure, doxycycline-inducible astrocyte-specific HIV Tat transgenic mice (iTat), a surrogate HAND model, were treated with PNU-125096, a positive allosteric modulator of α7 nicotinic acetylcholine receptor (α7 nAChR) and effects on Tat-induced behavioral impairments and neuropathologies were observed. This disclosure shows that PNU-125096 treatment significantly improved locomotor, learning and memory deficits of iTat mice while inhibited glial activation and increased PSD-95 expression in the cortex and hippocampus of iTat mice. α7 nAChR knockout eliminated the protective effects of PNU-125096 on iTat mice. In addition, inhibition of p38 phosphorylation by SB239063, a p38 MAPK-specific inhibitor, exacerbated Tat neurotoxicity in iTat mice. These findings demonstrated for the first time that α7 nAChR activation led to protection against HAND and suggest that α7 nAChR and PNU-125096 hold significant promise for development of therapeutics for HAND.